These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Thursky KA; Worth LJ; Seymour JF; Miles Prince H; Slavin MA Br J Haematol; 2006 Jan; 132(1):3-12. PubMed ID: 16371014 [TBL] [Abstract][Full Text] [Related]
4. Successful use of alemtuzumab in a child with refractory peripheral T-cell posttransplant lymphoproliferative disorder. Bartakke S; Abla O; Weitzman S J Pediatr Hematol Oncol; 2008 Oct; 30(10):787-8. PubMed ID: 19011483 [No Abstract] [Full Text] [Related]
5. Progress with alemtuzumab in chronic lymphocytic leukemia: Update from the 2003 meeting of the american society of hematology. Lee D Clin Lymphoma; 2004 Mar; 4(4):217-9. PubMed ID: 15072612 [No Abstract] [Full Text] [Related]
6. Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab. Vallejo C; Ríos E; de la Serna J; Jarque I; Ferrá C; Sánchez-Godoy P; Solano C; de la Cámara R; Rosell AI; Varela R; García MD; González-Barca E; López J; Pérez E; Ferrer S; Casado LF; Vázquez L; Villalón L; García-Marco JA Expert Rev Hematol; 2011 Feb; 4(1):9-16. PubMed ID: 21322774 [TBL] [Abstract][Full Text] [Related]
9. Rapid and durable molecular response of refractory T-cell large granular lymphocyte leukemia after alemtuzumab treatment. Monjanel H; Hourioux C; Arbion F; Colombat P; Lissandre S; Regner MP; Senecal D Leuk Res; 2010 Aug; 34(8):e197-9. PubMed ID: 20211489 [No Abstract] [Full Text] [Related]
10. Alemtuzumab for treatment of lymphoproliferative disorders. Haematologica; 2004 Dec; 89(12):1419. PubMed ID: 15590389 [No Abstract] [Full Text] [Related]
11. High incidence of tuberculosis after alemtuzumab treatment in Hong Kong Chinese patients. Au WY; Leung AY; Tse EW; Cheung WW; Shek TW; Kwong YL Leuk Res; 2008 Apr; 32(4):547-51. PubMed ID: 17714782 [TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab in T-cell lymphoproliferative disorders. Dearden CE; Matutes E Best Pract Res Clin Haematol; 2006; 19(4):795-810. PubMed ID: 16997184 [TBL] [Abstract][Full Text] [Related]
13. Advances in the use of alemtuzumab in CLL. Stilgenbauer S Clin Adv Hematol Oncol; 2008 Jan; 6(1):23-4. PubMed ID: 18322437 [No Abstract] [Full Text] [Related]
14. The role of alemtuzumab in the treatment of chronic lymphocytic leukemia. Zent CS Leuk Lymphoma; 2008 Feb; 49(2):175-6. PubMed ID: 18231900 [No Abstract] [Full Text] [Related]
15. Alemtuzumab, the first monoclonal antibody (MAb) directed against CD52. Keating M; Hallek M Med Oncol; 2002; 19 Suppl():S1-2. PubMed ID: 12180486 [No Abstract] [Full Text] [Related]
16. Buzz around Campath proof-of-concept trial in MS. Osborne R Nat Biotechnol; 2009 Jan; 27(1):6-8. PubMed ID: 19131976 [No Abstract] [Full Text] [Related]
17. Alemtuzumab: a new option for refractory chronic lymphocytic leukemia? Smith JA Cancer Pract; 2001; 9(4):211-3. PubMed ID: 11879313 [No Abstract] [Full Text] [Related]
18. Alemtuzumab. Am J Health Syst Pharm; 2001 Dec; 58(24):2372-3. PubMed ID: 11794950 [No Abstract] [Full Text] [Related]